Stocktoria
HALOZYME THERAPEUTICS, INC. HALO
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2003-01-30
HALOZYME THERAPEUTICS, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 33.6% | 54.3% | 40.7% | 40.5% | 62.2% |
| Net margin | 22.7% | 43.7% | 34.0% | 30.6% | 90.8% |
| FCF margin | 46.2% | 46.1% | 45.0% | 35.6% | 67.2% |
| Return on assets | 12.5% | 21.5% | 16.2% | 11.0% | 36.5% |
| Return on equity | 649.2% | 122.1% | 336.0% | 119.0% | 204.5% |
| Debt / equity | 43.89× | 4.14× | 17.89× | 8.87× | 4.00× |
| Current ratio | 4.66 | 7.80 | 6.64 | 5.65 | 7.91 |
| Revenue growth | 37.6% | 22.4% | 25.6% | 48.9% | 65.7% |
Source: SEC EDGAR filings · CIK 0001159036 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.